ECONOMIC BURDEN OF PSORIASIS AND DIABETES IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
Author(s)
Guerin A1, Latremouille-Viau D1, Day R2, Khan Z2, Zhang F21Analysis Group, Ltee., Montreal, QC, Canada, 2Celgene Corporation, Summit, NJ, USA
Presentation Documents
OBJECTIVES: Psoriasis, an immune mediated disorder with skin manifestations and comorbidities, has high resource requirement. Specifically, diabetes is highly prevalent in psoriasis patients and may represent a substantial incremental economic burden. This retrospective study aimed to estimate the incremental costs of psoriasis and diabetes in psoriasis patients. METHODS: Adult patients with psoriasis (i.e., ≥2 psoriasis diagnoses ICD-9 codes:696.1x) were selected from a large US administrative claims database. Psoriasis-free controls were matched with the psoriasis sample by age and gender in a 1:1 ratio. All patients were followed for one year to assess their healthcare costs. Incremental total healthcare costs (USD 2010) associated with psoriasis and diabetes in a psoriasis population, measured from a third-party payer perspective, were estimated using regression models controlling for age and gender. RESULTS: A total of 106,128 matched pairs were studied. Among psoriasis patients, 16% had diabetes compared to 13% of the psoriasis-free controls (p<.001). Psoriasis was associated with a $4,523 adjusted increment total health care costs among patients without diabetes ($10,017 vs. $5,539; p<.001), compared to $5,984 among patients with diabetes ($19,536 vs. $13,589; p<.001). In the psoriasis population, diabetes presented a $8,337 adjusted incremental cost compared to the psoriasis patients without diabetes ($19,536 vs. $10,017; p<.001). This was $1,460 more than the adjusted incremental costs from diabetes among controls without psoriasis (p<.001), representing an interaction of psoriasis and diabetes conditions, which significantly increases the health care costs. CONCLUSIONS: Both psoriasis and diabetes are expensive conditions to treat. The incremental economic burden of patients having both diseases is significantly higher than each condition individually, potentially due to the complexity of managing both conditions at the same time.
Conference/Value in Health Info
2011-11, ISPOR Europe 2011, Madrid, Spain
Value in Health, Vol. 14, No. 7 (November 2011)
Code
PSS13
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Sensory System Disorders